Maintenance treatment with infliximab for the management of Crohn's disease in adults.
Crohn's disease (CD) is a chronic, relapsing disease, the continuous cycle of which deeply affects the long-term course which, eventually, leads to fibrosis and development of transmural complications. It is well known that CD is an immune-mediated clinical condition and that tumor necrosis factor-alpha (TNF-alpha) plays a fundamental role in the pathogenesis of the disease. Current clinical guidelines recommend that patients with mild to moderate active CD should be treated initially with corticosteroids. Although this approach is effective in inducing remission, some patients may become dependent on, or refractory to, these drugs in the long term, thus increasing the risk of developing steroid-related adverse effects. A recent Cochrane systematic review established that infliximab (IFX) is effective in inducing remission in patients with CD. Although only a few published studies have assessed IFX for the maintenance of remission in the long term, there is evidence that IFX is superior to placebo in sustaining clinical remission and fistula healing; moreover, corticosteroid-sparing effects have been demonstrated. IFX is associated with the formation of antibodies to IFX which can lead to infusion reactions and shorter duration of response, but when comparing episodic vs scheduled maintenance treatment, the latter appears to sensibly reduce immunogenicity, thus offering improved efficacy and tolerance. The final point to consider is the best time to introduce IFX in the therapeutic algorithm of CD. Early use of IFX has been suggested to be more effective than late, and may potentially change the natural history of the disease. Effective induction and maintenance therapy with IFX is the only means with which to maintain long-lasting clinical and mucosal remission which, in turn, may modify the long-term course of the disease. Furthermore, when treating inflammatory bowel disease patients with IFX, an appropriate risk-benefit balance has to be taken into consideration, because the precise risk of serious adverse events associated with anti-TNF treatment in CD remains to be fully elucidated.
Caviglia
Renato
R
Department of Digestive Diseases, Campus Bio-Medico University of Rome, Rome, Italy.
Boskoski
Ivo
I
Cicala
Michele
M
Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6
17324398
Gastroenterology. 2006 Mar;130(3):940-87
16530532
Expert Opin Drug Saf. 2008 Sep;7(5):617-32
18759714
Cell. 2007 Oct 5;131(1):33-45
17923086
World J Gastroenterol. 2007 Oct 21;13(39):5238-44
17876895
Clin Gastroenterol Hepatol. 2006 Oct;4(10):1248-54
16931170
Gastroenterology. 2001 Aug;121(2):255-60
11487534
Aliment Pharmacol Ther. 2000 Dec;14(12):1553-9
11121902
Rev Gastroenterol Disord. 2004;4 Suppl 3:S18-24
15580149
Gastroenterology. 2008 Jun;134(7):1861-8
18440315
Aliment Pharmacol Ther. 2004 May 1;19(9):1019-24
15113369
Gastroenterol Clin North Am. 2002 Mar;31(1):1-20
12122726
Aliment Pharmacol Ther. 2002 Jan;16(1):51-60
11856078
N Engl J Med. 2004 Feb 26;350(9):876-85
14985485
Gut. 2007 Sep;56(9):1226-31
17229796
Mol Immunol. 2005 May;42(8):887-93
15829278
Clin Gastroenterol Hepatol. 2004 Jul;2(7):542-53
15224278
Cytokine. 1995 Apr;7(3):251-9
7640345
N Engl J Med. 2003 Feb 13;348(7):601-8
12584368
J Immunol. 2006 Feb 15;176(4):2617-24
16456024
Biomed Pharmacother. 2007 Jan;61(1):75-80
17184965
Am J Gastroenterol. 2006 May;101(5):1030-8
16606351
Gastrointest Endosc. 2006 Mar;63(3):433-42; quiz 464
16500392
Arthritis Rheum. 2006 Mar;54(3):702-10
16508926
Cochrane Database Syst Rev. 2004;(1):CD003574
14974022
Gastroenterology. 2010 Feb;138(2):463-8; quiz e10-1
19818785
Gastroenterology. 2006 Mar;130(3):650-6
16530505
Lancet. 2002 May 4;359(9317):1541-9
12047962
Dig Liver Dis. 2008 Jul;40 Suppl 2:S225-8
18598993
N Engl J Med. 1997 Oct 9;337(15):1029-35
9321530
Arthritis Rheum. 2006 Jan;54(1):26-37
16385520
Lancet. 2008 Jul 5;372(9632):67-81
18603161
Gastroenterology. 2003 Apr;124(4):917-24
12671888
Gastroenterology. 2006 Apr;130(4):1054-61
16618399
Gut. 2005 Feb;54(2):237-41
15647188
Lancet. 2008 Feb 23;371(9613):660-667
18295023
Gastroenterology. 2004 Feb;126(2):402-13
14762776
Arthritis Rheum. 2005 Nov;52(11):3381-90
16258899
Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53
18550004
Aliment Pharmacol Ther. 2005 Dec;22(11-12):1107-13
16305724
Gastroenterology. 1998 Jul;115(1):182-205
9649475
Inflamm Bowel Dis. 2007 Jun;13(6):769-96
17304581
N Engl J Med. 2008 Jan 31;358(5):528-30
18234759
Gastroenterology. 1999 Oct;117(4):761-9
10500056